Lansoprazole-induced subacute cutaneous lupus erythematosus

Panting, K.J.; Pinto, Mario; Ellison, J.

doi:10.1111/j.1365-2230.2008.03105.x

Cited by 16 publications

(8 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whether DI‐SCLE represents de novo development of pathogenic autoantibodies after drug exposure or an onset of disease in an already predisposed individual is unknown. Yet, Ro/SSA autoantibodies have been shown to be present long before clinical symptoms of LE, suggesting that certain suspected drugs are the last trigger needed for a subclinical disease to become evident in prone individuals 2,3,39,40 …”

Section: Discussionmentioning

confidence: 99%

Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden

Grönhagen

Fored

Linder

et al. 2012

British Journal of Dermatology

133

105

View full text Add to dashboard Cite

We found an association between drug exposure and SCLE. More than one third of the SCLE cases could be attributed to drug exposure. No significant OR was found for thiazides, which might be due to longer latency and therefore missed with this study design. DI-SCLE is reversible once the drug is discontinued, indicating the importance of screening patients with SCLE for potentially triggering drugs. A causal relationship cannot be established from this study and the underlying pathogenesis remains unclear.

show abstract

Section: Discussionmentioning

confidence: 99%

Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden

Grönhagen

Fored

Linder

et al. 2012

British Journal of Dermatology

133

105

View full text Add to dashboard Cite

show abstract

“…This drug has been implicated as a trigger for drug-induced subacute cutaneous lupus erythematosus (SCLE) [38]. In addition, protein pump inhibiting drugs such as lansoprazole can serve as a drug trigger for other clinical forms of ACTD displaying an interface dermatitis such as SCLE [39]. Protein pump inhibitors such as omeprazole have been reported to be capable of triggering DM as a drug-induced phenomenon [40].…”

Section: Discussionmentioning

confidence: 99%

Proximal nailfold microhemorrhage events are manifested as distal cuticular (eponychial) hemosiderin-containing deposits (CEHD) (syn. Maricq sign) and can aid in the diagnosis of dermatomyositis and systemic sclerosis

McBride¹,

Sontheimer

2016

Dermatology Online Journal

View full text Add to dashboard Cite

show abstract

“…Twelve cases have been reported: 5 with omeprazole [1,4,5,6], 5 with lansoprazole [1,7,8] and 2 with pantoprazole [1]. Moreover, in a Swedish population-based matched case-control study of 234 patients with SCLE, 65 received PPI.…”

Section: Discussionmentioning

confidence: 99%

Subacute Cutaneous Lupus Erythematosus Induced and Exacerbated by Proton Pump Inhibitors

Almebayadh

Régnier‐Rosencher²,

Carlotti³

et al. 2013

Dermatology

View full text Add to dashboard Cite

Background: Subacute cutaneous lupus erythematosus (SCLE) can be induced by numerous drugs. We report 3 cases of SCLE induced by proton pump inhibitors (PPIs). Objective: To highlight a rare cutaneous side effect induced by a frequently prescribed drug such as a PPI. Case Reports: Case 1 was a 30-year-old man who developed multiple annular plaques over the trunk and lower limbs 1 month after the initiation of pantoprazole. Antinuclear antibodies (ANA) were positive with anti-Ro/SSA and anti-La/SSB antibodies, and histology confirmed the diagnosis. Clinical improvement was achieved 8 weeks after the discontinuation of pantoprazole and the introduction of a treatment combining topical steroids and hydroxychloroquine. Lesions relapsed when pantoprazole was accidentally rechallenged. The second case was a 31-year-old woman, 28 weeks pregnant, who presented erythematous annular plaques over the trunk 7 weeks after starting esomeprazole. ANA and anti-Ro/SSA antibodies were positive, and the histology was compatible with SCLE. Fetal ultrasound was normal. She was treated with topical and oral steroids and hydroxychloroquine. Clinical improvement was achieved 4 weeks after the discontinuation of esomeprazole. The third case was a 57-year-old woman with systemic erythematosus lupus presenting annular and psoriasiform lesions on the trunk for 15 months. She was treated successively with hydroxychloroquine, azathioprine, mycophenolate mofetil and methotrexate with prednisone. A review of her drug history revealed the introduction of omeprazole a few weeks before the first appearance of skin lesions and omeprazole was contraindicated. Conclusion: SCLE should systematically be suspected in case of eruption after the introduction of PPI. The risk of fetal cardiac complications is important in pregnant women.

show abstract

Lansoprazole-induced subacute cutaneous lupus erythematosus

Cited by 16 publications

References 4 publications

Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden

Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden

Proximal nailfold microhemorrhage events are manifested as distal cuticular (eponychial) hemosiderin-containing deposits (CEHD) (syn. Maricq sign) and can aid in the diagnosis of dermatomyositis and systemic sclerosis

Subacute Cutaneous Lupus Erythematosus Induced and Exacerbated by Proton Pump Inhibitors

Contact Info

Product

Resources

About